High-Grade Serous Ovarian Cancer(HGSC)is the most prevalent and lethal form of gynecologic malignancies[1],accounting for 70%-80%of ovarian cancer fatalities.Despite decades of research,the overall survival rate for H...High-Grade Serous Ovarian Cancer(HGSC)is the most prevalent and lethal form of gynecologic malignancies[1],accounting for 70%-80%of ovarian cancer fatalities.Despite decades of research,the overall survival rate for HGSC has remained largely unchanged[2],and patients with advanced stages of the disease have only a 41%chance of surviving beyond five years[3].展开更多
基金supported in part by grants from the National Institutes of Health/National Cancer Institute(5U01CA213759-02,P30CA016672)the American Cancer Society,National Science Foundation(CHE-1411859)+1 种基金an endowment grant fromthe John P.Gaines Foundation.Dr.Cristian Rodriguez-Aguayo and Dr.Paola Amero were supported by the Brain SPORE Career Enhancement Program and NCI grant P50CA127001by the NIH through the Ovarian SPORE Career Enhancement Program and NCI grant P50CA217685.
文摘High-Grade Serous Ovarian Cancer(HGSC)is the most prevalent and lethal form of gynecologic malignancies[1],accounting for 70%-80%of ovarian cancer fatalities.Despite decades of research,the overall survival rate for HGSC has remained largely unchanged[2],and patients with advanced stages of the disease have only a 41%chance of surviving beyond five years[3].
